Want to join the conversation?
"Our leading multiple sclerosis portfolio, a growing hemophilia business, and our ongoing focus on managing expenses led to robust earnings growth in the first quarter," said $BIIB CEO George Scangos. "The remainder of 2016 will be an exciting period as we look to advance a number of potential breakthrough therapies in the clinic," Scangos added.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.